4TEEN4 Extends Series C Financing Round to €55 Million, Supporting Expanded Clinical Development of Procizumab in Cardiogenic Shock
- Combined capital will support the ongoing Phase 2a clinical trial of procizumab in cardiogenic shock
- Series C round was supported by both existing and new investors

